INTERVIEWS

Dr. Joaquin Mould-Quevedo, Global Pricing and Health Economics Director at Seqirus, a global leader in seasonal influenza prevention and pandemic influenza preparedness discusses data from two real-world studies demonstrating the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines. These findings were presented at Infectious Disease (ID) Week 2021 and further underscore the public health benefits of innovative technologies, including cell-based and adjuvanted technologies, in producing seasonal influenza vaccines, and reinforce the important role these vaccines play in reducing hospitalizations. 

Dr. Keyan Salari, MD, PhD., urologic oncologist and Co-Director, Prostate Cancer Genetics Program at the Massachusetts General Hospital and Harvard Medical School discusses a presentation from the American Urological Association (AUA) 2021 Annual Meeting titled “The Impact of a Positive Family History of Hereditary Cancer-Associated Malignancies on Outcomes of Active Surveillance for Prostate Cancer. 

Dr. Michael Agadjanyan is Vice President, Professor and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine (IMM), Huntington Beach, California, a non-profit scientific research organization focused on chronic human diseases, including neurodegenerative disorders. He has more than 20 years of experience in the central nervous system field and 47 years of experience in immunology. Today, Dr. Agadjanyan discusses the licensing of IMM’s universal vaccine platform technology, MultiTEP, to a new biotechnology startup, Nuravax. The ultimate goal is the developmentand commercialization of MultiTEP-based vaccines for the prevention of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other life-threatening and deadly neurodegenerative diseases.    

Dr. Allitia DiBernardo, MD, Global Head of Medical Affairs-Neuroscience at Janssen discusses a presentation at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress titled “Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population.” She talks about how this research may impact treatment decisions for early disease patients. 

Wound, ostomy and continence (WOC) nurse Joanna Burgess discusses her personal journey as a dual ostomate: receiving her first ostomy at just 3 years old and a second shortly after turning 30. She talks about the improvements she has seen in ostomy care as a WOC nurse, and the efforts by ostomy companies and organizations to raise awareness around the health and human rights of ostomates. In honor of World Ostomy Day on Oct. 2, global medical solutions company ConvaTec is raising awareness by encouraging all ostomates to share their stories on Instagram this October through #MyHealthyBonds.

Dr. Adam Feldman, MD, MPH, urologic oncologist at the Massachusetts General Hospital Department of Urology discusses his presentation from the 2021 American Urological Association’s (AUA) meeting titled “Trimodality Therapy for Management of Muscle Invasive Bladder Cancer” 

CU cancer center member Dan Pollyea, MD, MS, clinical director of leukemia services at the University of Colorado School of Medicine, discusses navigating patient care from initial diagnosis, through treatment, as well as new research into novel treatments that could benefit those in need. His patient Dave Cade, who was diagnosed with a type of blood cancer called acute myeloid leukemia (AML), details his journey to diagnosis and how innovative new research impacted his treatment plan.

Jill M. shares her journey battling HER2-positive metastatic breast cancer and her experience enrolled in the HER2CLIMB clinical trial.  She is joined by her physician, Dr.  Bhuvaneswari Ramaswamy, M.D., of the Ohio State University Comprehensive Cancer Center, who speaks to Jill’s treatment and the overall metastatic breast cancer treatment landscape. Learn more about TUKYSA.

Dr. Teresa Cody discusses her book: “You Healing You” about PRP (Platelet Rich Plasma). She’ll talk about how PRP has done some fantastic things for people in pain and with scars. 

Dr. Ifeyinwa Stitt, MD, Board Certified OBGYN discusses the first ever genetic assessment tool for ALL women to better understand their risk for breast cancer, regardless of ancestry. She talks about the differences from other current risk assessment options; and how it can help black, hispanic and asian women with a higher risk for breast cancer have the power to choose how to manage their risk of breast cancer.